SLC66A2: A Potential Drug Target for Alzheimer's, Parkinson's and Liver Cancer

Target Name: SLC66A2

NCBI ID: G80148

SLC66A2

SLC66A2: A Potential Drug Target for Alzheimer's, Parkinson's and Liver Cancer

SLC66A2 (Flj22378) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidney. It is a member of the SLC66 family, which is known for its role in intracellular signaling. SLC66A2 has been identified as a potential drug target or biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and liver cancer.

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and beta-amyloid plaques in the brain. These tangles and plaques are thought to contribute to the destruction of nerve cells in the brain, leading to the symptoms of Alzheimer's disease. SLC66A2 has been shown to be involved in the regulation of the aggregation of beta-amyloid peptides and neurofibrillary tangles, which may be important in the development and progression of Alzheimer's disease.

Parkinson's disease is a neurodegenerative disorder that is characterized by the loss of motor neurons in the brain. The most common cause of Parkinson's disease is the neurodegeneration that occurs in the brain, which is thought to be caused by the loss of dopamine-producing neurons. SLC66A2 has been shown to be involved in the regulation of dopamine release and uptake, which may be important in the development and progression of Parkinson's disease.

Liver cancer is a type of cancer that can arise from the liver cells or from the bile ducts. SLC66A2 has been shown to be involved in the regulation of cell growth and apoptosis, which may be important in the development and progression of liver cancer.

SLC66A2 has also been shown to be involved in a variety of other processes in the body, including the regulation of ion channels, neurotransmitter release, and cell signaling. It has been shown to interact with a wide range of molecules, including proteins, peptides, and small molecules.

Despite its potential as a drug target or biomarker, SLC66A2 is not yet a widely studied protein. There are currently only a few studies that have investigated the role of SLC66A2 in various biological processes. Further research is needed to fully understand the role of SLC66A2 in the development and progression of disease.

In conclusion, SLC66A2 is a protein that has been identified as a potential drug target or biomarker for several diseases, including Alzheimer's disease, Parkinson's disease, and liver cancer. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 66 Member 2

The "SLC66A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC66A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets